Lilly and Ambrx Inc. have entered into a collaboration to discover and develop novel treatments in several therapeutic areas, including metabolic diseases, central nervous system disorders and other diseases. The collaboration will apply Ambrx’s unique protein optimization technology, ReCODE, with Lilly’s expertise in biologics discovery, development and commercialization to pursue drug candidates, including therapeutic antibodies and improved variants of native proteins. Under th...